Valneva SE (VALN) Income from Continuing Operations (2021 - 2026)
Valneva SE (VALN) posted Income from Continuing Operations of 37521227.34 for Q1 2026, up 35.63% sequentially from 58294135.17 in Q4 2025, and down 285.29% YoY from 20249604.57 in Q1 2025.
Valneva SE (VALN) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Valneva SE has reported Income from Continuing Operations for 6 years, with the latest figure at 37521227.34 in Q1 2026.
- Quarterly Income from Continuing Operations fell 285.29% year-over-year to 37521227.34 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 160713858.59 (down 86.21% YoY) and the FY2025 annual result came in at 134119929.72, down 908.6% from the prior year.
- Income from Continuing Operations improved to 37521227.34 in Q1 2026 per VALN's latest filing, from 58294135.17 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 2159489241.55 in Q4 2022 and troughed at 2105670027.57 in Q3 2022.
- A 5-year average of 24902366.43 and a median of 28099969.45 in 2022 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 1015.58% in 2022, down 1033.13% in 2022.
- Over 5 years, Income from Continuing Operations stood at 2159489241.55 in 2022, then sank by 101.6% to 34596847.77 in 2023, then dropped by 14.43% to 39589322.39 in 2024, then tumbled by 47.25% to 58294135.17 in 2025, then surged by 35.63% to 37521227.34 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 37521227.34, 58294135.17, and 51757576.06 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn | -36.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -36.30 Mn |
| Mar 31, 2026 | -37.52 Mn |
| Dec 31, 2025 | -58.29 Mn |
| Sep 30, 2025 | -51.76 Mn |
| Jun 30, 2025 | -13.14 Mn |
| Mar 31, 2025 | -9.74 Mn |
| Dec 31, 2024 | -39.59 Mn |
| Sep 30, 2024 | -10.17 Mn |
| Jun 30, 2024 | -26.81 Mn |
| Mar 31, 2024 | 64.01 Mn |
| Dec 31, 2023 | -34.60 Mn |
| Sep 30, 2023 | -37.26 Mn |
| Jun 30, 2023 | -18.40 Mn |
| Mar 31, 2023 | -19.48 Mn |
| Dec 31, 2022 | 2.16 Bn |
| Sep 30, 2022 | -2.11 Bn |
| Jun 30, 2022 | -156.31 Mn |
| Mar 31, 2022 | -28.10 Mn |
| Dec 31, 2021 | 193.58 Mn |
| Sep 30, 2021 | -185.83 Mn |